Literature DB >> 12893111

Prevalence, etiology, and treatment of depression in Parkinson's disease.

William M McDonald1, Irene H Richard, Mahlon R DeLong.   

Abstract

Parkinson's disease (PD) is primarily a disease of elderly individuals with a peak age at onset of 55 to 66 years. It is characterized by bradykinesia, rigidity, tremor, and postural instability; and affects approximately 1 million individuals in the US and is the second most common neurodegenerative disease next to Alzheimer's disease. The motor symptoms of PD are the focus of pharmacotherapy, yet the nonmotor symptoms (e.g., dementia, psychosis, anxiety, insomnia, autonomic dysfunction, and mood disturbances) can be the most disturbing, disabling, and misunderstood aspects of the disease. Depressive symptoms occur in approximately half of PD patients and are a significant cause of functional impairment for PD patients. There is accumulating evidence suggesting that depression in PD is secondary to the underlying neuroanatomical degeneration, rather than simply a reaction to the psychosocial stress and disability. The incidence of depression is correlated with changes in central serotonergic function and neurodegeneration of specific cortical and subcortical pathways. Understanding comorbid depression in PD may therefore add to the understanding of the neuroanatomical basis of melancholia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12893111     DOI: 10.1016/s0006-3223(03)00530-4

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  79 in total

1.  Illness comorbidity as a biomarker?

Authors:  Hymie Anisman; Shawn Hayley
Journal:  J Psychiatry Neurosci       Date:  2012-07       Impact factor: 6.186

2.  Effects of depression and social support on comprehension and recall of informed consent information among Parkinson disease patients and their caregivers.

Authors:  Ellen J Teng; Nancy J Petersen; Christine Hartman; Ellen Matthiesen; Michael Kallen; Karon F Cook; Marvella E Ford
Journal:  Int J Psychiatry Med       Date:  2012       Impact factor: 1.210

Review 3.  Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

Authors:  Horrick Sharma; Soumava Santra; Aloke Dutta
Journal:  Future Med Chem       Date:  2015-11-30       Impact factor: 3.808

Review 4.  Stress, depression and Parkinson's disease.

Authors:  Ann M Hemmerle; James P Herman; Kim B Seroogy
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

Review 5.  Alternatives to levodopa in the initial treatment of early Parkinson's disease.

Authors:  Andrew Lees
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  Depression and intelligence in patients with Parkinson's disease and deep-brain stimulation.

Authors:  Courtney R Schadt; Katie L Cox; Michael G Tramontana; Daniel W Byrne; Thomas L Davis; John Y Fang; Peter E Konrad; Bhavna Padaliya; Robert W Mutter; Chandler E Gill; Caralee R Richardson; P David Charles
Journal:  J Natl Med Assoc       Date:  2006-07       Impact factor: 1.798

7.  Introduction: chronic medical conditions and depression--the view from primary care.

Authors:  Richard L Kravitz; Daniel E Ford
Journal:  Am J Med       Date:  2008-11       Impact factor: 4.965

8.  Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes.

Authors:  Sang Soo Cho; Kelly Aminian; Crystal Li; Anthony E Lang; Sylvain Houle; Antonio P Strafella
Journal:  Hum Brain Mapp       Date:  2016-08-29       Impact factor: 5.038

Review 9.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

10.  Nitric oxide synthase genes and their interactions with environmental factors in Parkinson's disease.

Authors:  Dana B Hancock; Eden R Martin; Jeffery M Vance; William K Scott
Journal:  Neurogenetics       Date:  2008-07-29       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.